Announcement under Regulation 30 (LODR)-Press Release / Media Release
Filed with BSE · ISIN INE365Y01019 · · 3 pages · English
Summary by 6ix AI
Bharat Parenterals Ltd. has announced that its subsidiary, Innoxel Lifesciences, has begun commercial supply to the U.S. market with its first product launched under a contract manufacturing arrangement. This marks a shift from licensing income to recurring revenue for Innoxel, which previously generated all its revenue from licensing agreements. The company expects more contract manufacturing product launches in the upcoming quarters, enhancing its revenue streams.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Bharat Parenterals Ltd. on 6ix
Story so far
Earlier from Bharat Parenterals
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Bharat Parenterals Ltd. Press Release Sep 29 2026
- Bharat Parenterals Ltd. Press Release Sep 19 2026
- Bharat Parenterals Ltd. Press Release Aug 28 2026
- Bharat Parenterals Ltd. Press Release Aug 27 2026
Later from Bharat Parenterals
- Shareholder Meeting / Postal Ballot-Outcome of EGM
- Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended On September 30, 2026.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
- Announcement under Regulation 30 (LODR)-Preferential Issue
Follow Bharat Parenterals into a list and get an email when it puts out news.
Follow Bharat Parenterals